The review is an attempt at critical evaluation of known synthetic procedures used for laboratory and industrial preparation of a synthetic antihypertensive -Dexmedetomidine as to their complexity, published yield and atom economy.
Introduction
Dexmedetomidine (1) -systemic name (S)-4- [1-(2,3-dimethylphenyl) ethyl]-3H-imidazole -represents a highly potent "α 2 -adrenoreceptor agonist", used in general management of patients undergoing surgery, as well as in intensive medicine. (Cormack et al., 2005) Dexmedetomidine has been commercially available under the trade names Precedex or Dexdor; inlike similar "α 2 -adrenoreceptor agonists" it offers suffi cient sedation accompanied by relatively infrequent side effect -"respiratory depression", allowing surgeries without artifi cial ventilation of the patient. Fig. 1 
Synthetic approaches to Dexmedetomidine
Dexmedetomidine (1) was fi rst prepared in 1987 by resolution of racemic medetomidine by enantiomerically pure (+)-tartaric acid. The thus obtained diastereomeric salts were separated by fractional crystallization in ethanol. (GB2206880) Preparation of Dexmedetomidine (1) published so far are based on fractional crystallization of diastereomeric salts of medetomidine (2) with the some optically active acids. An asymmetric synthesis of an optically pure product is yet to be published. That is why our analysis concentrates fi rst on synthetic procedures leading to racemic medetomidine (2) and fi nally on methods of separation of its enantiomers. The medetomidine (2) was fi rst prepared in the course of a diversifi ed search for novel, imidazole based, antihypertensives. (US4544664) (Scheme 1) In its fi rst steps the procedure involves a twofold addition of Grignard reagents, fi rst that of the substituted arylmagnesium bromide (4) to the methyl ester of the 4-imidazolecarboxylic acid (3), followed by that of methylmagnesium bromide to the formed ketone (5), resulting in the formation of the tertiary alcohol (6). Alcohol (6) has to be separated from the reaction mixture by a column chromatography, to the detriment of laboratory and even more of industrial manufacturing process. After dehydration of alcohol (6), followed by reduction of the ensuing double bond of the substituted styrene (7) medetomidine (2) is obtained. Details of hydroxylic group elimination or double bond reduction have been forgone by the authors. They give neither yields of single steps, nor the overall yield, making their procedure rather less attractive. The procedure nevertheless remains historically the fi rst one published. Kudzma and coworkers in 1991 selected another approach to the tertiary alcohol (6). (Kudzma et al., 1991) The appropriately protected imidazole (9) was used as nucleophile, whereas the chloride of benzoic acid (10) served as an electrophile. Protecting groups at the imidazole skeleton of the ketone (11) were removed by the action of 1.5 N hydrochloric acid The thus obtained deprotected ketone (12) was then transformed to the desired hydrochloride of medetonidine (2) by a sequence of reactions. This approach allowed a very good, 79 % overall yield of the target compound, although it involved at least three synthetic steps, all highly sensitive to the presence of moisture and carried out at low temperatures. Moreover, purifi cation of ketone (11) too required the use of chromatography. (Scheme 2)
Cordi and coworkers too applied 2,3-dimethylphenylmagnesium bromide (4) as a nucleophile. (Cordi et al., 1996) (Scheme 3) The addition at the protected imidazolecarbaldehyde (13) proceeds however only in rather unsatisfactory yield of 52 %. In the next step a relatively cheap oxidant (pyrolusite) is used to convert the prepared secondary alcohol to the ketone (14), needed in the subsequent addition of methylmagnesium bromide. The thus prepared tertiary alcohol (15), after elimination of water and reduction of the double bond affords medetomidine (2) in the overall yield of 41 %. The biggest single drawback of this procedure is the need of protecting group at the nitrogen of imidazolecarbaldehyde (13) Scheme 4 Scheme 5 construction of the imidazole ring, present in drug molecule (2). The second nitrogen of the imidazole ring comes from benzylamine. The reaction of benzylamine with nitroketone (25) affords the nitro enone (26), which after reduction with Raney nickel gives the corresponding endiamine (27). Cycli zation of diamine (27) with ethyl orthoformate gives rise to the derivative (28), containing an imidazole ring. Next, a standard reaction sequence (addition-elimination-reduction) was used to prepare medetomidine (2) via the styrene derivative (29), in the 13 % overall yield. Unfortunately the synthetic sequence is rather lengthy, affords low overall yield and requires two catalytic reductions. To make things worse the sequence does not allow the benefi t of simple preparation of analogs, containing a substituted imidazole or benzene ring. It is thus diffi cult to see its advantages for either laboratory synthesis, or, due to its drawn-out and cost-intensive character, for industrial scale manufacturing.
Separation of enantiomers of medetomidine
Authors of the above mentioned patents from 1987 (GB2206880, US4910214) deployed for the separation of enantiomers of medetomidine (2) by (+)-tartaric acid recurring fractional crystallization of diastereomeric salts from the mixture of methanol and ethanol. By repeated crystallization of the salt formed from mixing equivalents of medetomidine (2) and tartaric acid authors succeeded in isolating Dexmedetomidine (1) in 17 % overall yield. Although the number of successive crystallizations have not been specifi ed, they stop when the value of product optical rotation no longer rises. Another preparation involved the salts of medetomidine (2) with (+)-tartaric acid, (-)-mandelic acid and (-)-camphor-10-sulfonic acid. The best separation was achieved with tartrates. (US4910214) Comparison of relative bioactivity of enantiomers (after their liberation as free bases from diastereometic salts) showed that (S)-enantiomer demonstrated by 50 % higher in vitro activity than (R)-enantiomer, thus directing the interest of pharmaceutical companies towards the more active (S)-enantiomer of Dexmedetomidine (1). However, the patent does not disclose the yield and enantiomeric purity of Dexmedetomidine. Cordi and coworkers disclose preparation of Dexmedetomidine where resolution of medetomidine (2) was carried out by using mere 0.5 equivalent of (+)-tartaric acid in absolute ethanol to one equivalent of medetomidine (2). (Cordi et al., 1996) Dexmedetomidine (+)-tartarate was prepared after 4 crystallizations from ethanol in higher than 99 % enantiomeric excess and 21 % overall yield. Authors also describe the possibility to further improve the yield while preserving purity by markedly longer equilibration time of the mixture. As the process requires 5 days to provide Dexmedetomidine in very low overall yield it is industrially uneconomical. The chinese patent also discloses preparation of Dexmedetomidine (1) where medetomidine (2) was resolved by using
This process is also time consuming and requires highly expensive reagents thus making the process industrially uneconomical. Needless to say it is advantagenous to develop a short, high yielding and industrially viable process for preparation of highly pure Dexmedetomidine which eliminates use of expensive reagents. It is therefore an object of the new invention to overcome or ameliorate at least one disadvantage of the prior art or to provide an useful alternative. Another object of the invention is to provide a novel, concise, high yielding commertially viable and industrially applicable process for resolution of medetomidine to provide Dexmedetomidine in high yield and with high enantiomeric excess. Yet another object of the present invention is to provide a process for preparation of Dexmedetomidine having desirable pharmacological activity and broad safety margins, without toxicity or unfavorable side effects. In accordance with the above objectives, the newest patent provides a process for preparation of Dexmedetomidine. (WO2013069025) There are described fi ve steps: (i) reacting medetomidine with D-(-)-tartaric acid in the presence of solvent (the most preferred solvent is ethanol) (ii) fi ltering the resulting solution (iii) neutralizing the fi ltrate with a base (preferred is inorganic base selected from alkali metal carbonates or alkali metal bicarbonates, e.g. sodium bicarbonate) (iv) reacting the resulting product with L-(+)-tartaric acid to provide dexmedetomidine L-(+)-tartarate (v) reacting dexmedetomidine L-(+)-tartarate with a base (the most preferred base is sodium bicarbonate) The process of the invention provides Dexmedetomidine in 47 % yield and with enantiomeric excess of at least 99 %. The yield of Dexmedetomidine obtained by using the novel process is 2.2 times higher than that obtained by using resolution methods reported previously. All the steps of the process can be carried out in a single solvent and in a single base which are inexpensive. The process is thus economical. Dexmedetomidine is further converted into its hydrochloride salt. The pure Dexmedetomidine hydrochloride obtained by the above mentioned process may be formulated into a dosage form. In spite of low yields of Dexmedetomidine (1) in in procedures involving separation of medetomidine enantiomers (2) no synthetic procedure is known, leading directly to the desired enantiomer, starting either from optically pure starting compound, or using chiral auxiliaries in e.g. double bond reduction.
